AI Pathological Analysis System More Accurate than Humans in Reading Digital Biopsy Images

One in nine women in the developed world will be diagnosed with breast cancer at some point in her life. The prevalence of breast cancer is increasing, an effect caused in part by the modern lifestyle and increased life spans. Thankfully, treatments are becoming more efficient and more personalized. However, what isn’t increasing – and is in fact decreasing – is the number of pathologists, or the doctors whose specialization is examining body tissues to provide the specific diagnosis necessary for personalized medicine. Now, a team of researchers have made it their quest to turn computers into effective pathologists’ assistants, simplifying and improving the human doctor’s work.

The specific task that researchers at the Technion – Israel Institute of Technology (Haifa, Israel) have set out to achieve lies within the realm of immunotherapy. Immunotherapy has been gaining prominence in recent years as an effective, sometimes even game-changing, treatment for several types of cancer. The basis of this form of therapy is encouraging the body’s own immune system to attack the tumor. However, such therapy needs to be personalized as the correct medication must be administered to the patients who stand to benefit from it based on the specific characteristics of the tumor.

Multiple natural mechanisms prevent our immune systems from attacking our own bodies. These mechanisms are often exploited by cancer tumors to evade the immune system. One such mechanism is related to the PD-L1 protein – some tumors display it, and it acts as a sort of password by erroneously convincing the immune system that the cancer should not be attacked. Specific immunotherapy for PD-L1 can persuade the immune system to ignore this particular password, but of course would only be effective when the tumor expresses the PD-L1. It is a pathologist’s task to determine whether a patient’s tumor expresses PD-L1. Expensive chemical markers are used to stain a biopsy taken from the tumor in order to obtain the answer. The process is non-trivial, time-consuming, and at times inconsistent.

The Technion researchers took a different approach. In recent years, it has become an FDA-approved practice for biopsies to be scanned so they can be used for digital pathological analysis. The researchers decided to see if a neural network could use these scans to make the diagnosis without requiring additional processes. Neural networks are trained in a manner similar to how children learn: they are presented with multiple tagged examples. A child is shown many dogs and various other things, and from these examples forms an idea of what “dog” is.

The neural network developed by the Technion researchers was presented with digital biopsy images from 3,376 patients that were tagged as either expressing or not expressing PD-L1. After preliminary validation, it was asked to determine whether additional clinical trial biopsy images from 275 patients were positive or negative for PD-L1. It performed better than expected: for 70% of the patients, it was able to confidently and correctly determine the answer. For the remaining 30% of the patients, the program could not find the visual patterns that would enable it to decide one way or the other. Interestingly, in the cases where the artificial intelligence (AI) disagreed with the human pathologist’s determination, a second test proved the AI to be right.

“This is a momentous achievement,” explained Professor Ron Kimmel from the Henry and Marilyn Taub Faculty of Computer Science at the Technion. “The variations that the computer found – they are not distinguishable to the human eye. Cells arrange themselves differently if they present PD-L1 or not, but the differences are so small that even a trained pathologist can’t confidently identify them. Now our neural network can.”

“We expect AI to become a powerful tool in doctors’ hands,” added Prof. Kimmel. “AI can assist in making or verifying a diagnosis, it can help match the treatment to the individual patient, it can offer a prognosis. I do not think it can, or should, replace the human doctor. But it can make some elements of doctors’ work simpler, faster, and more precise.”

Related Links:
Technion

Visit expo >

Gold Member

Antipsychotic TDM Assays

Saladax Antipsychotic Assays

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Total 25-Hydroxyvitamin D₂ & D₃ Assay

25-OH-VD Reagent Kit

New

Troponin I Test

Quidel Triage Troponin I Test